Advances in direct-acting antiviral therapy for liver transplant recipients with HCV-related hepatocellular carcinoma
10.3969/j.issn.1001-5256.2021.10.039
- VernacularTitle:直接抗病毒药物治疗HCV相关肝细胞癌肝移植受者的研究进展
- Author:
Qian ZHU
1
;
Mingyuan ZHANG
1
;
Junqi NIU
1
Author Information
1. Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China
- Publication Type:Reviews
- Keywords:
Carcinoma, Hepatocellular;
Hepacivirus;
Liver Transplantation;
Antiviral Agents
- From:
Journal of Clinical Hepatology
2021;37(10):2444-2447
- CountryChina
- Language:Chinese
-
Abstract:
The launch of direct-acting antiviral agents is a milestone in the treatment of hepatitis C, but further studies are needed to explore its specific timing and effectiveness in liver transplantation for HCV-related hepatocellular carcinoma (HCC). This article summarizes related guidelines, consensus statements, and recommendations in China and globally and the advantages of different treatment timing strategies. Furthermore, a retrospective analysis of related studies is performed to investigate the controversial topic of the impact of direct-acting antiviral agents on the recurrence rate of HCV-related HCC after liver transplantation, and it is pointed that direct-acting antiviral agents can reduce the risk of HCC recurrence in liver transplant recipients with HCV-related HCC. The selection of treatment timing should consider various factors such as liver function, waiting time for donors, and utilization of HCV-positive organs.
